🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are increasing globally, with estimates suggesting over 82 million new cases each year. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the context of growing infection rates, the spread of superbugs and the highly restricted therapeutic options at this time.”

Health officials are deeply concerned about the rise in drug-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Authorization

Zoliflodacin, marketed under the name a brand name, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts hope that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This treatment, which is also used to treat UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This approval represents a major breakthrough in the management of superbug gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Clinical Trial Results and Worldwide Availability

As per results published in a major medical journal, the new drug eradicated more than 90% of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which involves two antibiotics. The study included over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the rights to register and commercialise the drug in many regions with limited resources.

Doctors treating patients have expressed hope. The availability of a one-pill regimen like this is hailed as a "game-changer" for managing the epidemic. This is considered crucial to lessen the impact of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.